Better Therapeutics was a company focused on developing prescription digital therapeutics (PDT) to address cardiometabolic diseases, primarily type 2 diabetes. They aimed to create mobile apps with cognitive behavioral therapy (CBT) programs to deliver therapy directly to patients through their smartphones. The Company developed a proprietary platform for the development of FDA-regulated, software-based solutions for T2D, heart disease and other conditions. The CBT delivered by Better Therapeutics’ PDTs is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. The company went public in 2023, trading under the symbol BTTX on the Nasdaq Stock Market.